Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma

Neoplasma

Volumn 60, Issue 2, 2013, Pages 135-142

  Qi, J ^a   Wang, J ^b   Katayama, H ^b   Sen, S ^b   Liu, S M ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biomarkers; Circulating microRNAs (cmiRNAs); Diagnosis and prognosis; HCC

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 101; MICRORNA 122; MICRORNA 125B; MICRORNA 146A; MICRORNA 15B; MICRORNA 16; MICRORNA 182; MICRORNA 200A; MICRORNA 21; MICRORNA 221; MICRORNA 222; MICRORNA 223; MICRORNA 24; MICRORNA 29B; MICRORNA 323; MICRORNA 34A; MICRORNA 375; MICRORNA 449; MICRORNA 521; MICRORNA 610; MICRORNA 618; MICRORNA 640; MICRORNA 9; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; TRANSCRIPTION FACTOR CDX2; TRANSCRIPTION FACTOR GATA 6; UNCLASSIFIED DRUG; UNINDEXED DRUG; TUMOR MARKER;

ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CELL PROLIFERATION; CLINICAL PRACTICE; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; EARLY DIAGNOSIS; HUMAN; LIVER CELL CARCINOMA; MICROARRAY ANALYSIS; MORBIDITY; MORTALITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR INVASION; BLOOD; LIVER TUMOR; PROGNOSIS;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MICRORNAS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878793883     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2013_018     Document Type: Article

References (70)

1. PARKIN DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-543. http://dx.doi.org/10.1016/S1470-2045(01)00486-7
2. WANG J, CHAN JY, FONG CC, TZANG CH, FUNG KP et al. Transcriptional analysis of doxorubicin-induced cytotoxicity and resistance in human hepatocellular carcinoma cell lines. Liver Int 2009; 29: 1338-1347. http://dx.doi.org/10.1111/j.1478-3231.2009.02081.x
3. BOREL F, KONSTANTINOVA P, JANSEN PL. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol 2012; 56: 1371-1383. http://dx.doi.org/10.1016/j.jhep.2011.11.026
4. BOSCH FX, RIBES J, CLERIES R, DIAZ M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005; 9: 191-211. http://dx.doi.org/10.1016/j.cld.2004.12.009
5. GRAMANTIERI L, FORNARI F, CALLEGARI E, SABBIONI S, LANZA G et al., MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med. 2008; 12: 2189-2204. http://dx.doi.org/10.1111/j.1582-4934.2008.00533.x
6. REBOUISSOU S, BIOULAC-SAGE P, ZUCMAN-ROSSI J. Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J Hepatol. 2008; 48: 163-170. http://dx.doi.org/10.1016/j.jhep.2007.10.003
7. TANAKA M, KATAYAMA F, KATO H, TANAKA H, WANG J et al. Hepatitis B and C Virus Infection and Hepatocellular Carcinoma in China: A Review of Epidemiology and Control Measures. J Epidemiol 2011; 21: 401-416 http://dx.doi.org/10.2188/jea.JE20100190
8. SCHWARTZ M, ROAYAIE S, KONSTADOULAKIS M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol 2007; 4: 424-432. http://dx.doi.org/10.1038/ncponc0844
9. POON RT, FAN ST. Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome. Liver Transpl 2004; 10: S39-45. http://dx.doi.org/10.1002/lt.20040
10. YUEN MF, CHENG CC, LAUDER IJ, LAM SK, OOI CG et al. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000; 31: 330-335. http://dx.doi.org/10.1002/hep.510310211
11. FUKUDA S, ITAMOTO T, NAKAHARA H, KOHASHI T, OHDAN H et al. Clinicopathologic features and prognostic factors of resected solitary small-sized hepatocellular carcinoma. Hepatogastroenterology 2005; 52: 1163-1167.
12. JELIC S, SOTIROPOULOS GC. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21: v59-64. http://dx.doi.org/10.1093/annonc/mdq166
13. COLLIER J, SHERMAN M. Screening for hepatocellular carcinoma. Hepatology 1998; 27: 273-278. http://dx.doi.org/10.1002/hep.510270140
14. OKA H, TAMORI A, KUROKI T, KOBAYASHI K, YAMAMOTO S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994; 19: 61-66. http://dx.doi.org/10.1002/hep.1840190111
15. ABDALLA MA, HAJ-AHMAD Y. Promising Candidate Urinary MicroRNA Biomarkers for the Early Detection of Hepatocellular Carcinoma among High-Risk Hepatitis C Virus Egyptian Patients. J Cancer. 2012; 3: 19-31. http://dx.doi.org/10.7150/jca.3.19
16. KASAHARA A, HAYASHI N, FUSAMOTO H, KAWADA Y, IMAI Y et al. Clinical valuation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes. Dig Dis Sci 1993; 38: 2170-2176. http://dx.doi.org/10.1007/BF01299891
17. CHOI J, PARK Y, KIM JH, KIM HS. Evaluation of automated serum des-gamma-carboxyprothrombin (DCP) assays for detecting hepatocellular carcinoma. Clin Biochem 2011; 44: 1464-1468. http://dx.doi.org/10.1016/j.clinbiochem.2011.08.1144
18. BRUIX J, LLOVET JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35: 519-524. http://dx.doi.org/10.1053/jhep.2002.32089
19. WANG J, SEN S. MicroRNA functional network in pancreatic cancer: From biology to biomarkers of disease. J Biosci 2011; 36: 481-491. http://dx.doi.org/10.1007/s12038-011-9083-4
20. SCHETTER AJ, LEUNG SY, SOHN JJ, ZANETTI KA, BOWMANED, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma, JAMA. 2008; 299: 425-436. http://dx.doi.org/10.1001/jama.299.4.425
21. SEIKE M, GOTO A, OKANO T, BOWMAN ED, SCHETTER AJ, et al. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers, Proc. Natl. Acad. Sci. U. S. A. 2009; 106: 12085-12090. http://dx.doi.org/10.1073/pnas.0905234106
22. LIU C, YU J, YU S, LAVKER RM, CAI L, et al. MicroRNA-21 acts as an oncomir through multiple targets in human hepatocellular carcinoma. J Hepatol. 2010; 53: 98-107. http://dx.doi.org/10.1016/j.jhep.2010.02.021
23. WANG B, MAJUMDER S, NUOVO G, KUTAY H, VOLINIA S, et al. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology 2009; 50: 1152-1161. http://dx.doi.org/10.1002/hep.23100
24. ZHANG Y, WEI W, CHENG N, WANG K, LI B, et al. Hepatitis C Virus-induced upregulation of miR-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology 2012; doi: 10.1002/hep.25849. [Epub ahead of print]. http://dx.doi.org/10.1002/hep.25849
25. HAN ZB, CHEN HY, FAN JW, WU JY, TANG HM, et al. Upregulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. J Cancer Res Clin Oncol. 2012; 138: 153-161. http://dx.doi.org/10.1007/s00432-011-1076-z
26. GAROFALO M, QUINTAVALLE C, ROMANO G, CROCE CM, CONDORELLI G. miR221/222 in cancer: their role in tumor progression and response to therapy. Curr Mol Med. 2012; 12: 27-33. http://dx.doi.org/10.2174/156652412798376170
27. PINEAU P, VOLINIA S, MCJUNKIN K, MARCHIO A, BATTISTON C, et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A. 2010; 107: 264-269. http://dx.doi.org/10.1073/pnas.0907904107
28. YUAN Q, LOYA K, RANI B, MOBUS S, BALAKRISHNAN A, et al. MicroRNA-221 overexpression accelerates hepatocyte proliferation during liver regeneration. Hepatology. 2012; [Epub ahead of print] http://dx.doi.org/10.1002/hep.25984
29. WONG QW, CHING AK, CHAN AW, CHOY KW, TO KF, et al. MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin Cancer Res. 2010; 16: 867-875. http://dx.doi.org/10.1158/1078-0432.CCR-09-1840
30. WANG B, HSU SH, MAJUMDER S, KUTAY H, HUANG W, et al. TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene 2010; 29: 1787-1797. http://dx.doi.org/10.1038/onc.2009.468
31. JI J, YAMASHITA T, BUDHU A, FORGUES M, JIA HL, et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 2009; 50: 472-480. http://dx.doi.org/10.1002/hep.22989
32. CHEN XM. MicroRNA signatures in liver diseases. World J Gastroenterol 2009; 15: 1665-1672. http://dx.doi.org/10.3748/wjg.15.1665
33. KIM CJ, PARK NH, CHUNG YH. Roads towards a new tailored therapy for hepatocellular carcinoma: diagnostic, therapeutic and prognostic implications of microRNAs. Liver Int. 2012; 32: 695-697. http://dx.doi.org/10.1111/j.1478-3231.2012.02779.x
34. KIM WH, MIN KT, JEON YJ, KWON CI, KO KH et al. Association study of microRNA polymorphisms with hepatocellular carcinoma in Korean population. Gene 2012; 504: 92-97. http://dx.doi.org/10.1016/j.gene.2012.05.014
35. AUGELLO C, VAIRA V, CARUSO L, DESTRO A, MAGGIONI M et al. MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma. Liver Int 2012; 32: 772-782. http://dx.doi.org/10.1111/j.1478-3231.2012.02795.x
36. XU J, ZHU X, WU L, YANG R, YANG Z et al. MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/β-catenin pathway. Liver Int 2012; 32: 752-760. http://dx.doi.org/10.1111/j.1478-3231.2011.02750.x
37. DATTA J, KUTAY H, NASSER MW, NUOVO GJ, WANG B et al. Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res 2008; 68: 5049-5058. http://dx.doi.org/10.1158/0008-5472.CAN-07-6655
38. KIM S, LEE UJ, KIM MN, LEE EJ, KIM JY et al. MicroRNA miR-199a* regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2). J Biol Chem 2008; 283: 18158-18166. http://dx.doi.org/10.1074/jbc.M800186200
39. MORITA K, TAKETOMI A, SHIRABE K, UMEDA K, KAYASHIMA H et al. Clinical significance and potential of hepatic microRNA-122 expression in hepatitis C. Liver Int 2011; 31: 474-484. http://dx.doi.org/10.1111/j.1478-3231.2010.02433.x
40. CHANG J, NICOLAS E, MARKS D, SANDER C, LERRO A et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 2004; 1: 106-113. http://dx.doi.org/10.4161/rna.1.2.1066
41. GRAMANTIERI L, FERRACIN M, FORNARI F, VERONESE A, SABBIONI S et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007; 67: 6092-6099. http://dx.doi.org/10.1158/0008-5472.CAN-06-4607
42. FORNARI F, GRAMANTIERI L, GIOVANNINI C, VERONESE A, FERRACIN M et al. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 2009; 69: 5761-5767. http://dx.doi.org/10.1158/0008-5472.CAN-08-4797
43. LI S, FU H, WANG Y, TIE Y, XING R et al. MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellularcarcinoma. Hepatology 2009; 49: 1194-1202. http://dx.doi.org/10.1002/hep.22757
44. BALA S, MARCOS M, SZABO, G. Emerging role of microRNAs in liver diseases. World J Gastroenterol 2009; 15: 5633-5640. http://dx.doi.org/10.3748/wjg.15.5633
45. XIONG Y, FANG JH, YUN JP, YANG J, ZHANG Y et al. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010; 51: 836-845.
46. CHEN X, BA Y, MA L, CAI X, YIN Y et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006. http://dx.doi.org/10.1038/cr.2008.282
47. MITCHELL PS, PARKIN RK, KROH EM, FRITZ BR, WYMAN SK et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-10518. http://dx.doi.org/10.1073/pnas.0804549105
48. LU J, GETZ G, MISKA EA, ALVAREZ-SAAVEDRA E, LAMB J et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838. http://dx.doi.org/10.1038/nature03702
49. XI Y, NAKAJIMA G, GAVIN E, MORRIS CG, KUDO K et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 2007; 13: 1668-1674. http://dx.doi.org/10.1261/rna.642907
50. LI J, SMYTH P, FLAVIN R, CAHILL S, DENNING K et al. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffinembedded (FFPE) cells and snap frozen cells. BMC Biotechnol 2007; 7: 36. http://dx.doi.org/10.1186/1472-6750-7-36
51. SHEN J, TODD NW, ZHANG H, YU L, LINGXIAO X et al. Plasma microRNAs as potential biomarkers for non-smallcell lung cancer. Lab Invest 2011; 91: 579-587. http://dx.doi.org/10.1038/labinvest.2010.194
52. ZHANG C, WANG C, CHEN X, YANG C, LI K et al. Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. Clin Chem 2010; 56: 1871-1879. http://dx.doi.org/10.1373/clinchem.2010.147553
53. WANG J, CHEN J, CHANG P, LEBLANC A, LI D, ABBRUZZESSE JL et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila) 2009; 2: 807-813. http://dx.doi.org/10.1158/1940-6207.CAPR-09-0094
54. WEBER JA, BAXTER DH., ZHANG S, HUANG DY, HUANG KH et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010; 56: 1733-1741. http://dx.doi.org/10.1373/clinchem.2010.147405
55. CORTEZ MA, BUESO-RAMOS C, FERDIN J LOPEZ-BERESTEIN G, SOOD AK et al. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011; 8: 467-477. http://dx.doi.org/10.1038/nrclinonc.2011.76
56. PARK NJ, ZHOU H, ElashoffD, HENSONBS, KASTRATOVIC DA et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res 2009; 15: 5473-5477. http://dx.doi.org/10.1158/1078-0432.CCR-09-0736
57. LIU AM, YAO TJ, WANG W, WONG KF, LEE NP et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open 2012; 2: e000825.
58. XU J, WU C, CHE X, WANG L, YU D et al. Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011; 50: 136-142. http://dx.doi.org/10.1002/mc.20712
59. QI P, CHENG SQ, WANG H, LI N, CHEN YF et al. Serum MicroRNAs as Biomarkers for Hepatocellular Carcinoma in Chinese Patients with Chronic Hepatitis B Virus Infection. PLoS One 2011; 6: e28486. http://dx.doi.org/10.1371/journal.pone.0028486
60. QU KZ, ZHANG K, LI H, AFDHAL NH, ALBITAR M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol 2011; 45: 355-360.
61. LI J, WANG Y, YU W, CHEN J, LUO J. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Biophys Res Commun 2011; 4: 406: 70-73. http://dx.doi.org/10.1016/j.bbrc.2011.01.111
62. TOMIMARU Y, EGUCHI H, NAGANO H, WADA H, KOBAYASHI S et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol 2012; 56: 167-175. http://dx.doi.org/10.1016/j.jhep.2011.04.026
63. LI LM, HU ZB, ZHOU ZX, CHEN X, LIU FY et al. Serum microRNA Profiles Serve as Novel Biomarkers for HBV Infection and Diagnosis of HBV-Positive Hepatocarcinoma. Cancer Res 2010; 70: 9798-9807. http://dx.doi.org/10.1158/0008-5472.CAN-10-1001
64. BOUTZ DR, COLLINS PJ, SURESH U, LU M, RAMIREZ CM et al. Two-tiered approach identifies a network of cancer and liver disease-related genes regulated by miR-122. J Biol Chem. 2011; 286: 18066-18078. http://dx.doi.org/10.1074/jbc.M110.196451
65. KUTAY H, BAI S, DATTA J, MOTIWALA T, POGRIBNY I et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 2006; 99: 671-678. http://dx.doi.org/10.1002/jcb.20982
66. TSAI WC, HSU PW, LAI TC, CHAU GY, LIN CW et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 2009; 49: 1571-1582. http://dx.doi.org/10.1002/hep.22806
67. COULOUARN C, FACTOR VM, ANDERSEN JB, DURKIN ME, THORGEIRSSON SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009; 28: 3526-3536. http://dx.doi.org/10.1038/onc.2009.211
68. BAI S, NASSER MW, WANG B, HSU SH, DATTA J et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem 2009; 284: 32015-32027. http://dx.doi.org/10.1074/jbc.M109.016774
69. MARRERO JA, FENG Z, WANG Y, NGUYEN MH, BEFELER AS et al. Alphafetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009; 137: 110-118. http://dx.doi.org/10.1053/j.gastro.2009.04.005
70. GUI J, TIAN Y, WEN X, ZHANG W, ZHANG P et al., Serum microRNA characterization identifiesmiR-885-5p as a potential marker for detecting liver pathologies. Clin Sci (Lond) 2011; 120: 183-193. http://dx.doi.org/10.1042/CS20100297